AKTS Stock Forecast & Price Target

Aktis Oncology is emerging as a leader in the oncology field, with a promising pipeline of targeted alpha radiopharmaceuticals for solid tumors. Recent data from competitors in this field further reinforce the potential of this approach, while the company's collaboration agreements provide a steady stream of revenue. Based on a DCF valuation, we give Aktis Oncology a $33 per share price objective, with potential catalysts in the next year including dose escalation results from their Phase 1b trial, clinical imaging and dosimetry results from AKY-2519, and commencement of IND-enabling studies for two earlier stage programs.

Aktis Oncology is facing challenges in its pipeline development, with significant financial losses and delays in advancing pipeline candidates into registrational programs. Its valuation relies heavily on the successful approval of its two main products, AKY-1189 and AKY-2519, and any negative clinical results would impact its market value. Additionally, the company faces competition from other radioimmunotherapy/radioligand therapy modalities, which poses a risk to its market share. These factors contribute to our negative outlook on Aktis Oncology's stock.